What Semaglutide Is and Why the Approval Status Matters
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone the gut releases after eating, signaling the pancreas to release insulin and telling the brain to reduce appetite. The FDA has approved specific branded versions: Ozempic for type 2 diabetes management, Wegovy for chronic weight management, and Rybelsus as an oral tablet for type 2 diabetes. Those approvals apply to those specific products, manufactured under strict pharmaceutical controls, prescribed by a licensed clinician.
This distinction matters a lot for safety triage. Compounded semaglutide and research-chemical semaglutide sold through peptide vendors are not FDA-approved. The FDA issued multiple warnings between 2023 and 2024 about compounded semaglutide products containing semaglutide sodium or acetate salt forms, which are not the same molecule used in approved drugs. Purity, concentration, and sterility are not guaranteed outside the regulated supply chain. If you're reading this because someone offered you semaglutide outside a pharmacy or clinic, that gap in oversight is the first safety question to sit with.
The clinical trial record for the approved forms is genuinely large. The SUSTAIN and STEP trial programs enrolled thousands of participants across multiple countries and ran for periods ranging from 68 weeks to several years. That scale of human data is unusual in the peptide and metabolic compound space, and it gives us a clearer picture of both benefits and harms than most compounds discussed on sites like this one.
What the Clinical Trials Document About Side Effects
The most consistently reported side effects across the STEP trials were gastrointestinal. In STEP 1, a 68-week randomized controlled trial published in the New England Journal of Medicine in 2021 with 1,961 participants, nausea affected approximately 44% of the semaglutide group compared with 16% in the placebo group. Diarrhea, vomiting, and constipation were also significantly more common in the treatment arm. Most GI events were described as mild to moderate and tended to decrease over time, but they were common enough that roughly 7% of participants in the semaglutide group discontinued the trial due to them.
Gallbladder-related events are a documented concern. The STEP 1 trial reported cholelithiasis (gallstones) in 1.6% of the semaglutide group versus 0.7% in the placebo group. A 2022 meta-analysis in the journal Obesity Reviews looked across GLP-1 receptor agonist trials and found a statistically significant increase in gallbladder disease risk. Rapid weight loss itself is a known gallstone risk factor, so it is not fully clear how much is attributable to the drug versus the weight change it produces, but the signal is real and worth knowing.
Heart rate increases have also been observed. Across multiple trials, semaglutide was associated with a mean increase in resting heart rate of roughly 1 to 4 beats per minute. For most people this is clinically minor, but it is a documented physiological effect. The SUSTAIN-6 cardiovascular outcomes trial, published in the New England Journal of Medicine in 2016, followed 3,297 participants with type 2 diabetes and high cardiovascular risk over about two years and found a reduction in major adverse cardiovascular events, but also confirmed the heart rate signal. Anyone with an arrhythmia history should have a specific conversation with their cardiologist before any GLP-1 therapy.
The Boxed Warning: Thyroid Tumors
Every FDA-approved semaglutide product carries a boxed warning, which is the most serious warning the FDA places on a drug label. The warning concerns medullary thyroid carcinoma (MTC). In rodent studies, semaglutide caused dose-dependent and duration-dependent thyroid C-cell tumors. The FDA and the drug's manufacturer, Novo Nordisk, state that it is unknown whether semaglutide causes thyroid C-cell tumors in humans, because the human relevance of the rodent findings has not been established.
Because the risk cannot be ruled out, semaglutide is contraindicated in people with a personal or family history of MTC and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are hard stops, not soft cautions. If either applies to you or a family member, this compound is off the table regardless of what form it comes in.
The FDA also advises patients to report any neck lumps, hoarseness, difficulty swallowing, or shortness of breath to a doctor promptly while using semaglutide. These can be symptoms of thyroid problems. This is one of the clearest examples in the GLP-1 space of a known animal signal that has not been resolved in humans, and it deserves to be taken seriously rather than dismissed because the human data is not yet definitive.
Who Should Be Most Cautious?
Beyond the MTC contraindication, several populations appear in the prescribing information as requiring extra care. People with a history of pancreatitis are one group. Acute pancreatitis has been reported in GLP-1 receptor agonist trials, and while a causal link has not been definitively established in large studies, the prescribing information for Wegovy and Ozempic advises discontinuing the drug if pancreatitis is suspected. Anyone with a prior pancreatitis episode should discuss this risk explicitly with a gastroenterologist or endocrinologist.
People with diabetic retinopathy are another group flagged in the data. SUSTAIN-6 found a higher rate of diabetic retinopathy complications in the semaglutide group (3.0%) compared with placebo (1.8%). Rapid improvement in blood sugar control is a known trigger for short-term worsening of retinopathy, and this appears to be the likely mechanism. It does not mean people with diabetes and retinopathy cannot use semaglutide, but it does mean ophthalmology monitoring is part of the safety picture.
Pregnancy is a clear caution zone. Animal studies showed fetal harm at doses used in those studies, and Wegovy's prescribing information advises discontinuing the drug at least two months before a planned pregnancy. There is no adequate human data on semaglutide use during pregnancy. Women of childbearing age should discuss contraception and timing with their prescriber. This is not a compound to continue without a direct conversation if pregnancy is possible or planned.
People who are already lean, who have a history of eating disorders, or who have significant cardiovascular disease outside the specific populations studied in trials are also groups where the risk-benefit picture is less clear. The large trials enrolled specific populations, and the safety data applies most directly to people who resemble those populations.
What We Still Do Not Know
Long-term safety data beyond five years is still limited. The SELECT trial, a cardiovascular outcomes trial published in the New England Journal of Medicine in 2023 with over 17,000 participants followed for a mean of 34 months, added meaningful data on cardiovascular safety in people with obesity and established cardiovascular disease. But questions about very long-term effects on thyroid tissue, pancreatic function, and muscle mass with repeated use cycles remain open.
The safety profile of compounded and research-chemical semaglutide is genuinely unknown in ways that go beyond the drug itself. Impurities, incorrect concentrations, and non-sterile preparation add layers of risk that the clinical trial data does not address. The FDA's 2023 and 2024 alerts specifically called out dosing errors with compounded products leading to hospitalizations. That is not a theoretical concern.
There is also limited data on semaglutide use in adolescents outside the specific trials that studied it in that age group, in people over 75, and in people with severe kidney or liver disease. The approved prescribing information notes that no dose adjustment is required for renal or hepatic impairment based on pharmacokinetic data, but clinical safety data in those populations is thinner than in the core trial populations.